Every report comes from a Lived member, sent anonymously.
Have you tried Blood transfusion therapy for beta-Thalassemia?
Blood transfusion therapy gives a person donated blood, or one part of it, through an IV line in a vein. Most transfusions use red blood cells, which carry oxygen around the body. When someone has too few working red cells (anemia), tissues get less oxygen. Donor red cells raise the hemoglobin level, the oxygen-carrying protein measured on a routine blood count, and ease the effects of anemia. A transfusion does not fix the reason the person was anemic, so the benefit lasts only until the hemoglobin drifts down again. Some people need a transfusion once, after surgery, an injury or during a serious illness. Others need it regularly because their body cannot make enough healthy red cells, as in severe thalassemia, or because their own red cells cause harm, as in sickle cell disease. In sickle cell disease, transfusion works partly by dilution: replacing a share of the stiff, sickle-shaped cells with flexible donor cells lowers the chance that small blood vessels become blocked. An exchange transfusion goes further by removing some of the person's own red cells while donor cells are given. Platelet and plasma transfusions, which help blood clot, follow the same basic process but serve different purposes. This page focuses on red cells.
Occasional transfusion is used for heavy blood loss from surgery or injury and for severe anemia caused by blood disorders, some cancers and their treatment. In the hospital, the decision rests on symptoms together with the hemoglobin level, which is reported in grams per deciliter (g/dL). For most stable adults in the hospital, transfusion is considered when hemoglobin falls below about 7 g/dL. A slightly higher cutoff of 7.5 to 8 g/dL may be used around heart or orthopedic surgery, or for people who already have heart disease. Regular, scheduled transfusion is a long-term treatment for two main groups. People with transfusion-dependent thalassemia, an inherited condition in which the body makes too little normal hemoglobin, often need it throughout life. People with sickle cell disease may receive it to prevent a first or repeat stroke, especially children whose transcranial Doppler ultrasound (a painless scan that measures how fast blood moves through the brain's arteries) shows a high stroke risk. Transfusion is also used in sickle cell disease before surgery, during some pregnancies, and when complications continue despite hydroxyurea, a daily oral medicine for the condition.
Before a first transfusion, a blood sample is tested for blood type, and before each one the blood bank checks that the donor unit is compatible with the person's blood (a cross-match). People expected to need many transfusions usually have more detailed red cell typing at the start, so later units can be matched more closely. The care team explains the reasons, risks and alternatives, and people sign consent and may decline. A nurse places an IV line in an arm vein, or uses an existing central line or port. Blood runs slowly at first while staff check temperature, pulse and blood pressure, then faster if all is well, with further checks along the way. A red cell transfusion usually takes one to four hours, and people who are not otherwise in the hospital generally go home the same day. Regular transfusion for thalassemia usually means an infusion visit every two to four weeks, timed so hemoglobin does not fall too low in between. Guidelines aim to keep it above roughly 9 to 10.5 g/dL before each transfusion. In sickle cell disease, ongoing treatment may instead be an exchange transfusion, often done with an automated machine called a cell separator that removes some of the person's red cells and replaces them with donor cells, lowering the share of sickle hemoglobin. These sessions are commonly scheduled every three to six weeks. People on regular simple transfusions, as in thalassemia and many people with sickle cell disease, also need iron chelation, medicine that binds excess iron so the body can get rid of it. Exchange transfusion adds much less iron because it removes the person's own red cells, and their iron, as donor cells go in, so people on it often need less chelation, and some need none; the same iron monitoring decides. The options are deferasirox, a once-daily pill; deferiprone, a pill that can lower white blood cells and so needs regular blood counts; and deferoxamine, given slowly under the skin, usually overnight with a small portable pump.
After a single transfusion, how much better someone feels depends on why they were anemic and whether that cause is being treated. The arm used for the IV may be sore or bruised for a day or two. Regular transfusion becomes a routine built around the calendar: a blood count and antibody check before each session, an infusion visit lasting several hours, and the hemoglobin gradually drifting down until the next one. In thalassemia, the goal of a well-planned schedule is good energy levels and normal growth and development in children, while also quieting the bone marrow's overwork that can otherwise thicken and weaken bones. Iron monitoring is a permanent part of care. A blood test called ferritin, which reflects how much iron the body has stored, is checked every one to three months, and the trend matters more than any single result. Magnetic resonance imaging (MRI) scans measure iron in the liver, and in the heart where needed, usually every one to two years depending on the results. The heart, liver and hormone-producing glands are also checked periodically, since iron damage can appear as diabetes, thyroid problems or low sex hormones. Chelation doses are adjusted as these numbers change. In sickle cell disease, transfusions started to prevent stroke are usually continued for years. Some children who began transfusions because of a high-risk ultrasound can later move to hydroxyurea after a period of transfusion. For people who have already had a stroke, switching away from transfusion appears to raise the risk of another stroke and other sickle cell complications, so that decision belongs with a hematologist.
For hospital transfusion, more blood is not better for most people. Across 45 randomized trials in about 20,600 adults, waiting until hemoglobin fell to about 7 to 8 g/dL instead of 9 to 10 g/dL did not worsen important outcomes in most patient groups, and it meant fewer transfusions. This evidence is of moderate certainty and underpins current guidelines. The clearest long-term benefit is stroke prevention in children with sickle cell anemia, the most common severe form of sickle cell disease. In a landmark trial of 130 high-risk children identified by Doppler ultrasound, 11 strokes occurred with standard care compared with 1 among children receiving regular transfusions. A later trial in children with silent strokes (small areas of brain injury seen only on MRI) found that new strokes or silent strokes occurred in 6% of transfused children versus 14% of those observed, over about three years. A Cochrane review rates the evidence for stroke prevention in high-risk children as moderate and finds lower-certainty evidence for fewer episodes of acute chest syndrome, a serious lung complication. There is no trial evidence for adults, or for children with other forms of sickle cell disease, and most expert recommendations on transfusion in sickle cell disease are conditional because direct, high-certainty evidence is scarce. In transfusion-dependent thalassemia, regular transfusion is the main treatment, and its success depends on controlling iron. Guidelines grade the evidence that chelation improves survival and lowers the risk of heart failure as strong.
Iron overload is the defining long-term risk of regular simple transfusion. Each unit of red cells given this way brings iron the body has no way to excrete, so it accumulates and, without treatment, damages the heart, liver and hormone glands, leading to heart failure, cirrhosis, liver cancer, diabetes and growth problems. Chelation prevents most of this, but only when taken consistently, and preventing buildup works better than trying to remove iron later because some damage is permanent. Chelation medicines have their own side effects and monitoring. Repeated transfusions can lead the immune system to make antibodies against donor red cells (alloimmunization). This is more common in sickle cell disease and can make compatible blood harder to find, which is why extended matching and a lasting record of a person's antibodies matter, especially when care moves between hospitals. In sickle cell disease, a delayed reaction can appear days to weeks after a transfusion and is easily mistaken for a pain crisis, so the care team should always know about a recent transfusion. Most reactions are mild, such as fever, chills, itching or hives. Serious ones are uncommon: destruction of the donor cells from a mismatch, a severe allergic reaction, or fluid overload in people with heart or kidney disease. Blood is screened carefully, and the chance of catching an infection from a transfusion is low. During the transfusion, telling the nurse right away about chills, fever, itching, trouble breathing, or chest or back pain lets staff stop it and check for a reaction. Because reactions can also start the next day or weeks later, contact the care team promptly for a new fever, dark or reddish urine, yellow skin or eyes, severe back pain or a new rash after going home. Swelling of the lips, tongue or face, or severe difficulty breathing, needs emergency care by calling 911. Regular transfusion also takes time, reliable IV access and frequent visits. For some people, other options can reduce or replace it: luspatercept, an injected medicine that can lower how many transfusions some adults with thalassemia need, and a stem cell transplant, which can cure thalassemia or sickle cell disease for a minority of people with a well-matched donor.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience with Blood transfusion therapy, what's helped you, or ask the community a question.